Genlight Medical Raises Hundreds of Millions of Yuan in Financing
Genlight Medical has completed its C and D financing rounds, raising several hundred million yuan. The funds are intended to advance the company's epilepsy treatment and spinal interface technologies.
Genlight Medical has concluded its C and D financing rounds, securing a total of several hundred million Chinese yuan. The C round was led by Qiming Venture Partners, with the D round seeing participation from investors including Saizhi Bole, Kuanqiao Hengsong, and Ningbo State Capital.
The company intends to utilize the capital raised to accelerate the registration and commercialization of its Epilcure implantable neurostimulation system, designed for drug-resistant focal epilepsy. Funds will also support the clinical translation of its Vivastep spinal interface and facilitate overseas regulatory filings and clinical collaborations.
The Epilcure system, targeting epilepsy treatment, represents a key area of Genlight Medical's development. Additionally, the Vivastep technology offers potential advancements in treating spinal cord injuries and other neurological conditions. This funding is expected to aid in expanding the company's global reach and product pipeline.